Clinical Trial

Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Primary completion pushed: 2026-05-28 -> 2026-07-29 2026-07-31
notable Primary completion pushed: 2026-03-19 -> 2026-05-28 2026-05-02
Trial Details
NCT Number NCT07443631
Lead Sponsor Philip Morris Products S.A.
Conditions Smoking
Enrollment 108 participants
Start Date 2026-02-19
Primary Completion 2026-07-29 (estimated)
Study Completion 2026-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-30